BioCryst Pharmaceuticals,Inc. (BCRX)

[apollo1452]

CEO says Galidesivir & Berotralstat news "this summer"
Galidesivir+Berotralstat+Factor D+Rapivab = $20+
1) Berotralstat Japanese Sakigake approval expected 3Q 2020, BCRX will receive $20M milestone from partner Torii
2) Berotralstat HAE Expanded Access Program initiated, PDUFA Dec 2020
https://ir.biocryst.com/node/21431/pdf
3) BCRX hires 16 HAE managers/sales reps from
competitor Takeda for Berotralstat commercialization
4) Rapivab approved for Flu
https://www.biocryst.com/our-program/rapivab/
5) Galidesivir COVID-19 clinical trial news due this summer, Gali beats Ebola & Zika viruses
https://www.researchgate.net/publication/320203179_Efficacy_of_Galidesivir_against_Ebola_Virus_Disease_in_Rhesus_Monkeys
https://ir.biocryst.com/news-releases/news-release-details/galidesivir-stops-zika-viral-replication-primate-model
7) Galidesivir COVID-19 animal study news overdue, FDA Animal Rule another path for Gali Emergency Use
Authorization.
8) Oral Factor D inhibitor "pipeline in a molecule" for complement-mediated diseases granted FDA Fast Track
https://ir.biocryst.com/node/21516/pdf
9)FOP Connective Tissue Disease Phase 1 results 2H
2020
https://www.webmd.com/children/what-is-fop#1
10) $220M Cash On Hand last update
11) Insider Trading Report
https://fintel.io/n/us/bcrx